Burlington Arcade, Primark and Belstaff owners top fashion arm of Sunday Times Rich List
The list may not be definitive as it it's based on identifiable wealth and not private things like bank accounts. But it's still the best option out there to find just who's making big money from fashion.
David and Simon Reuben with a fortune of almost £27 billion are second on the overall list but are the top fashion-linked names. They own Burlington Arcade, the upmarket central London shopping destination that hosts some of fashion and beauty's top brands.
The extended Weston family — Guy, George, Alannah and Galen Weston and family — is the second fashion name with a combined fortune of almost £18 billion. They rose two places this time to number six. They control Primark and Fortnum & Mason (and Holt Renfrew in Canada).
Behind them at number seven on over £17 billion is INEOS tycoon Sir Jim Ratcliffe with his company not primarily focused on fashion but making the fashion grade by controlling the Belstaff label.
The Duke of Westminster and the Grosvenor family are at number 14 with a net worth of almost £10 billion. While their property interests are diverse, the fact that they own fast tracks of land in central London makes them one of the key fashion retail landlords there. And their ownership of many luxury enclaves in the West End underlines that.
At number 23 on £7.7 billion is Anders Holch Povlsen along with his family. He has big stakes in ASOS and Debenhams Group as well as controlling most of Topshop and owning the giant Danish Bestseller business.
Also high up on the list at number 28 are Pentland and JD Sports ' Stephen Rubin and family on £6.66 billion; Earl Cadogan and family at number 30 with £6.1 billion (they own the Cadogan estate which induces Sloane street and the King's Road); and Zuber and Mohsin Issa on £6 billion whose purchase of Asda a few years ago also bought them the George at Asda label.
A bit further down, Laurence and Francois Graff of the luxury jewellery brand are on £3.65 billion; Baron Howard de Walden and family who control big parts of the Marylebone shopping district are on £3.2 billion; Mike Ashley who owns most of Frasers Group is on £3.1 billion; and River Island 's Bernard Lewis and family are on £2.7 billion.
New to this year's list are Castore founders Tom and Phil Beahon. They may only be in 345th place with their joint £350 million fortune, but chances are they'll rise higher in the list as the years go by.
Other current and past key names further down the list, all with fortunes in the hundreds of millions, are Barbour 's Dame Margaret and Helen Barbour; Matt and Jodie Moulding of THG; Chrissie Rucker and Nick Wheeler of The White Company and Charles Tyrwhitt; David and Victoria Beckham; Matches founders Tom and Ruth Chapman; and Andrew Killingsworth of Yours Clothing.
Meanwhile, Gymshark founder Ben Francis is number four in the The Sunday Times 35 Under 35 Rich List, with his wealth valued at £900 million.
Also on the 35 under 35 list are some names likely to be on the main list at some point. They include Lounge Underwear co-founders Daniel and Melanie Marsden on £151 million; footballer turned fashion entrepreneur Reece Wabara of Manière De Voir at £83 million, and AYBL founders Reiss and Kristian Edgerton at £60 million.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fashion Network
4 days ago
- Fashion Network
Pandora second quarter operating profit in line with forecast, keeps 2025 outlook
By Reuters Danish jewellery maker Pandora posted second-quarter operating profit in line with expectations on Friday, and stuck to its full-year growth forecast. "In these turbulent times, we are satisfied with yet another quarter of high single-digit organic growth and strong profitability," CEO Alexander Lacik said in a statement. "Despite the macroeconomic challenges to top and bottom line, we are confident that we will deliver on our targets for the year driven by an exciting product pipeline, new marketing campaigns and operational agility," he said. Operating profit for the second quarter was 1.29 billion Danish crowns ($201.6 million), the same as forecast by analysts in a poll gathered by the company. Organic revenue growth stood at 8%, also in line with analyst expectations. The charm bracelet maker stuck to its full-year guidance of 7-8% organic sales growth and an operating profit margin at around 24%. © Thomson Reuters 2025 All rights reserved.
Fashion Network
4 days ago
- Fashion Network
Pandora second quarter operating profit in line with forecast, keeps 2025 outlook
Danish jewellery maker Pandora posted second-quarter operating profit in line with expectations on Friday, and stuck to its full-year growth forecast. "In these turbulent times, we are satisfied with yet another quarter of high single-digit organic growth and strong profitability," CEO Alexander Lacik said in a statement. "Despite the macroeconomic challenges to top and bottom line, we are confident that we will deliver on our targets for the year driven by an exciting product pipeline, new marketing campaigns and operational agility," he said. Operating profit for the second quarter was 1.29 billion Danish crowns ($201.6 million), the same as forecast by analysts in a poll gathered by the company. Organic revenue growth stood at 8%, also in line with analyst expectations. The charm bracelet maker stuck to its full-year guidance of 7-8% organic sales growth and an operating profit margin at around 24%.
Euronews
06-08-2025
- Euronews
Novo Nordisk keeps growing, fuelling hopes of a stock rebound
Novo Nordisk reported results for the first half of 2025 on Wednesday, days after issuing a profit warning that triggered a 23% single-day share price plunge — the steepest in its history. The results were broadly in line with expectations. In the first six months of 2025, Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant exchange rates (CER) to DKK 154.9bn (€20.77bn). US sales climbed 16% in kroner (17% at CER), boosted by accounting changes. This included a DKK 3bn (€402 million) provision in the second quarter linked to the US' 340B drug discount scheme. International sales also rose 16% (19% at CER). Sales in Diabetes and Obesity care, meanwhile, grew 16% to DKK 145.4bn (€19.49bn), driven by a 56% surge in obesity treatments to DKK 38.8 billion (€5.2bn). GLP-1 diabetes drugs rose 8%, and rare disease sales increased 14%. Valuation slump In July 2024, Danish pharmaceutical giant Novo Nordisk briefly touched a €600bn valuation, becoming Europe's most valuable company and even surpassing its country's gross domestic product. Just over a year later, its market capitalisation has collapsed to around €180bn, as cracks begin to emerge in the blockbuster narrative surrounding its weight-loss drugs. Yet some Wall Street analysts argue the sell-off may have gone too far. At current levels, they suggest the company could be entering value territory, potentially offering a compelling buying opportunity. Forecasts for the year ahead Looking ahead, Novo Nordisk's 2025 sales are expected to grow 8–14% at CER, with operating profit up 10–16%. Currency effects are seen trimming those gains by 3 and 5 percentage points respectively. The lowered forecast reflects reduced demand for GLP-1 diabetes and weight-loss therapies due to alternative products from competitors — especially affecting Wegovy and Ozempic in the US and selected global markets. Meanwhile, leadership changes at Novo Nordisk will take effect this Thursday. After Lars Fruergaard Jørgensen was ousted in May linked to the firm's falling share price, Maziar Mike Doustdar will take over as CEO this week. Analysts eye buying opportunity after historic sell-off Goldman Sachs analyst James Quigley noted that the results were largely in line with the pre-release and exchange-rate pressures on operating profit were slightly less severe than initially feared. However, the firm flagged the discontinuation of several pipeline assets. These are individually minor, but collectively raising some concern about long-term research and development momentum. Quigley remained broadly optimistic on Novo Nordisk's long-term potential growth: "At the current level, we believe the sell-off is disconnected from the long-term opportunity in the obesity market, particularly given the significant manufacturing infrastructure and investments Novo is making or has already made.' Goldman Sachs acknowledged that uncertainties remain around the GLP-1 and obesity market, as well as Novo Nordisk's pipeline strength, particularly in light of the eventual semaglutide patent expiry. The firm said it would continue tracking key data points and developments closely. Still, Quigley added that, following the sharp share price drop, the risk-reward balance had shifted favourably. "On balance, we see more upside than downside risk and remain Buy-rated," the note read, with a DKK 400 (€53.62) target price implying about 29% upside from current levels. Market reaction Novo Nordisk shares were trading 2% lower during European morning trading on Wednesday, eyeing their seventh negative day out of the last eight. Shares are now down over 65% compared with a year ago.
